OLIG2 (Gene)

Organism:

Homo sapiens

Synonyms:BHLHB1, ENTREZ:10215, HGNC:9398, MIM:606386, NM_005806, NP_005797, OLIG2, OLIGO2, PRKCBP2, RACK17, XM_005260908, XP_005260965, bHLHe19, oligodendrocyte transcription factor 2

Id:ENSG00000205927

Entrez:10215

Ensembl:ENSG00000205927

Description:oligodendrocyte transcription factor 2

This gene encodes a basic helix-loop-helix transcription factor which is expressed in oligodendroglial tumors of the brain. The protein is an essential regulator of ventral neuroectodermal progenitor cell fate. The gene is involved in a chromosomal translocation t(14;21)(q11.2;q22) associated with T-cell acute lymphoblastic leukemia. Its chromosomal location is within a region of chromosome 21 which has been suggested to play a role in learning deficits associated with Down syndrome. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View OLIG2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with OLIG2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using OLIG2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for OLIG2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with OLIG2.

Results found

Linked to

	Label	Description
	GSE102505 5 V 0 TUNICAMYCIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE142210 11 V 10 PANOBINOSTAT HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 7 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE142210 3 V 5 PANOBINOSTAT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE201309 5 V 0 MATRINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE234148 HDAC inhibition 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 9 v 14 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 11 V 6 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE102505 5 V 0 TUNICAMYCIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 cisplatin 11 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE142210 11 V 10 PANOBINOSTAT HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 cisplatin 7 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE142210 3 V 5 PANOBINOSTAT HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE201309 5 V 0 MATRINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE234148 HDAC inhibition 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 4 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 9 v 14 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 11 V 6 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.